3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Tumor-Agnostic
1
Conditions
Breast Neoplasms
14
Neoplasms by Site
2
Neoplasms
2
Neoplasm Metastasis
2
Breast Diseases
2
Advanced Breast Cancer
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Diseases
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
Paclitaxel
50
Capecitabine
50
Trastuzumab
38
Fulvestrant
31
pembrolizumab
27
Cyclophosphamide
27
Carboplatin
27
Gemcitabine
23
Letrozole
21
palbociclib
19
Docetaxel
19
Lapatinib
18
Bevacizumab
18
exemestane
17
eribulin
15
Everolimus
14
abemaciclib
13
Vinorelbine
13
Nivolumab
13
Magnetic Resonance Spectroscopy
12
Cisplatin
12
Anastrozole
12
trastuzumab deruxtecan
11
Zoledronic Acid
11
Doxorubicin
11
Albumin-Bound Paclitaxel
11
olaparib
10
Tamoxifen
10
Specimen Handling
10
Radiotherapy
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
AZD9833
×
Breast
×
Clear all
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled
NCT04711252
2025-10-14
SERENA-4
AstraZeneca
Phase 3
Active not recruiting
1,370 enrolled